Drug Information

Drug (ID: DG01867) and It's Reported Resistant Information

• Name: ERK inhibitors
• Synonyms: ERK inhibitors
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: GTPase Nras (NRAS) [2]

• Molecule Alteration: Missense mutation; p.G12C (c.34G>T)
• Sensitive Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• Experimental Note: Revealed Based on the Cell Line Data
• Experiment for Molecule Alteration: DNA sequencing assay
• Experiment for Drug Resistance: Fluorescence-activated cell sorting assay
• Mechanism Description: The missense mutation p.G12C (c.34G>T) in gene NRAS cause the sensitivity of ERK inhibitors by unusual activation of pro-survival pathway

Biliary tract cancer [ICD-11: 2C15]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) [1]

• Molecule Alteration: Missense mutation; p.L485W (c.1799T>A)
• Sensitive Disease: Biliary tract cancer [ICD-11: 2C15.0]
• Experimental Note: Identified from the Human Clinical Data

Head and neck cancer [ICD-11: 2D42]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) [1]

• Molecule Alteration: Missense mutation; p.G469A (c.1454T>G)
• Sensitive Disease: Head and neck cancer [ICD-11: 2D42.0]
• Experimental Note: Identified from the Human Clinical Data

References

• Ref 1: Survival outcomes for various treatment modalities in advanced-stage grade 3 follicular lymphoma (FL3): A National Cancer Database (NCDB) study.
• Ref 2: Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitorsCancer Discov. 2013 Jul;3(7):742-50. doi: 10.1158/2159-8290.CD-13-0070. Epub 2013 Apr 24.